NOVA:FRA
Novo Nordisk A/S
34,42 €
arrow_upward
+0,76%(+0,26) 1K
20-okt, 22:00:00 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoNOVA tikeri uchun statistika yaratilmoqda...
Ochish
33,96 €
Yuqori
34,50 €
Past
33,96 €
Bozor kapitali
133,92 mlrd
Oʻrtacha hajm
1,12 ming
Hajmi
351,00
52 haftalik eng yuqori
54,80 €
52 haftalik eng past
30,45 €
Xodimlar soni
67 ming
Ochish
33,96 €
Yuqori
34,50 €
Past
33,96 €
Bozor kapitali
133,92 mlrd
Oʻrtacha hajm
1,12 ming
Hajmi
351,00
52 haftalik eng yuqori
54,80 €
52 haftalik eng past
30,45 €
Xodimlar soni
67 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
TipRanks
·
3 soat oldin
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data
24/7 Wall St.
·
5 soat oldin
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
Traders Union
·
7 soat oldin
What's behind Novo Nordisk's latest 2.1% stock surge?
The Globe and Mail
·
9 soat oldin
Novo Nordisk Expands 2026 Share Buyback, Lifting Treasury Stake to 1.2%
Profil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Novo Nordisk A/S haqida
CEOMike Doustdar
Xodimlar soni66,7 ming
Asos solingan1923
Bosh ofislarBagsværd, Capital Region of Denmark, Daniya
Sektor-
Veb-saytnovonordisk.com